Sutro Biopharma Inc
Research Sutro Biopharma Inc (STRO) on Bullrun: market cap USD 236.54M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSTRO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 236.54M
- Financial periodQ2 2026
- RevenueUSD 9.84M
- Net income-USD 38.53M
- Free cash flow-USD 38.29M
Valuation Snapshot
latest market cap is USD 236.54M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 102.48M | -USD 191.00M | -USD 178.93M | n/a | -22.49 | USD 58.13M | USD 15.67M | -USD 132.45M |
| FY2024 | USD 62.04M | -USD 227.00M | -USD 194.64M | n/a | -29.4 | USD 190.30M | USD 23.15M | USD 44.60M |
| FY2023 | USD 153.73M | -USD 107.00M | -USD 115.93M | n/a | -1.78 | USD 69.27M | USD 4.06M | USD 149.65M |
| FY2022 | USD 67.77M | -USD 119.20M | -USD 4.31M | n/a | -2.35 | USD 47.25M | USD 16.27M | USD 217.05M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 236.54M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 99.32M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 151.85M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 261.49M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 464.40M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 689.35M | n/a | n/a | n/a |
About Sutro Biopharma Inc
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sutro Biopharma Inc's market cap?
Sutro Biopharma Inc's market capitalization is USD 236.54M.
What does Sutro Biopharma Inc do?
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer.